Bert Scoccia1, Habibe Demir, Yuna Kang, Michelle A Fierro, Nicola J Winston. 1. Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Illinois College of Medicine, 820 South Wood St., Chicago, IL 60612-7313, USA. bscocc@uic.edu
Abstract
BACKGROUND: Untreated hypothyroidism can lead to ovulatory dysfunction resulting in oligo-amenorrhea. Treatment with levothyroxine can reverse such dysfunction and thus should improve fertility. The purpose of this retrospective study was to assess whether in vitro fertilization (IVF) pregnancy rates differ in levothyroxine-treated women with hypothyroidism compared to women without thyroid dysfunction/disorders. METHODS: Treated hypothyroid and euthyroid women undergoing IVF at an academic IVF center were studied after Institutional Review Board approval. Women with hypothyroidism were treated with levothyroxine 0.025-0.15 mg/day for at least 3 months to maintain baseline thyrotropin (TSH) levels of 0.35-4.0 μU/mL prior to commencing IVF treatment (HYPO-Rx group). Causes of infertility were similar in both groups with the exception of male factor, which was more common in the HYPO-Rx group. The main outcomes studied were implantation rate, clinical pregnancy rate, clinical miscarriage rate, and live birth rate. RESULTS: We reviewed the first IVF retrieval cycle performed on 240 women aged 37 years or less during the period January 2003 to December 2007. Women with treated hypothyroidism (n=21) had significantly less implantation, clinical pregnancy, and live birth rates than euthyroid women (n=219). CONCLUSIONS: We conclude that, despite levothyroxine treatment, women with hypothyroidism have a significantly decreased chance of achieving a pregnancy following IVF compared to euthyroid patients. A larger prospective study is necessary to assess confounding variables, confirm these findings, and determine the optimal level of TSH prior to and during controlled ovarian hyperstimulation for IVF.
BACKGROUND: Untreated hypothyroidism can lead to ovulatory dysfunction resulting in oligo-amenorrhea. Treatment with levothyroxine can reverse such dysfunction and thus should improve fertility. The purpose of this retrospective study was to assess whether in vitro fertilization (IVF) pregnancy rates differ in levothyroxine-treated women with hypothyroidism compared to women without thyroid dysfunction/disorders. METHODS: Treated hypothyroid and euthyroid women undergoing IVF at an academic IVF center were studied after Institutional Review Board approval. Women with hypothyroidism were treated with levothyroxine 0.025-0.15 mg/day for at least 3 months to maintain baseline thyrotropin (TSH) levels of 0.35-4.0 μU/mL prior to commencing IVF treatment (HYPO-Rx group). Causes of infertility were similar in both groups with the exception of male factor, which was more common in the HYPO-Rx group. The main outcomes studied were implantation rate, clinical pregnancy rate, clinical miscarriage rate, and live birth rate. RESULTS: We reviewed the first IVF retrieval cycle performed on 240 women aged 37 years or less during the period January 2003 to December 2007. Women with treated hypothyroidism (n=21) had significantly less implantation, clinical pregnancy, and live birth rates than euthyroid women (n=219). CONCLUSIONS: We conclude that, despite levothyroxine treatment, women with hypothyroidism have a significantly decreased chance of achieving a pregnancy following IVF compared to euthyroid patients. A larger prospective study is necessary to assess confounding variables, confirm these findings, and determine the optimal level of TSH prior to and during controlled ovarian hyperstimulation for IVF.
Authors: D W Cramer; P M Sluss; R D Powers; P McShane; E S Ginsburgs; M D Hornstein; A F Vitonis; R L Barbieri Journal: J Assist Reprod Genet Date: 2003-06 Impact factor: 3.412
Authors: T Bjoro; J Holmen; O Krüger; K Midthjell; K Hunstad; T Schreiner; L Sandnes; H Brochmann Journal: Eur J Endocrinol Date: 2000-11 Impact factor: 6.664
Authors: G E Krassas; N Pontikides; T Kaltsas; P Papadopoulou; J Paunkovic; N Paunkovic; L H Duntas Journal: Clin Endocrinol (Oxf) Date: 1999-05 Impact factor: 3.478
Authors: Erik K Alexander; Ellen Marqusee; Jennifer Lawrence; Petr Jarolim; George A Fischer; P Reed Larsen Journal: N Engl J Med Date: 2004-07-15 Impact factor: 91.245
Authors: Marcos Abalovich; Nobuyuki Amino; Linda A Barbour; Rhoda H Cobin; Leslie J De Groot; Daniel Glinoer; Susan J Mandel; Alex Stagnaro-Green Journal: J Clin Endocrinol Metab Date: 2007-08 Impact factor: 5.958
Authors: Sarah C Baumgarten; Scott M Convissar; Michelle A Fierro; Nicola J Winston; Bert Scoccia; Carlos Stocco Journal: J Clin Endocrinol Metab Date: 2014-05-21 Impact factor: 5.958
Authors: Anatte E Karmon; Eden R Cardozo; Irene Souter; Julie Gold; John C Petrozza; Aaron K Styer Journal: J Assist Reprod Genet Date: 2016-02-04 Impact factor: 3.412
Authors: Andrea Weghofer; Eric Himaya; Vitaly A Kushnir; David H Barad; Norbert Gleicher Journal: Reprod Biol Endocrinol Date: 2015-05-15 Impact factor: 5.211
Authors: Carlo Saccardi; Salvatore Gizzo; Kathrin Ludwig; Maria Guido; Mara Scarton; Michele Gangemi; Raffaele Tinelli; Pietro Salvatore Litta Journal: Biomed Res Int Date: 2013-08-22 Impact factor: 3.411
Authors: Andrea Weghofer; David H Barad; Sarah Darmon; Vitaly A Kushnir; Norbert Gleicher Journal: Reprod Biol Endocrinol Date: 2016-05-10 Impact factor: 5.211
Authors: Birgit Jatzko; Elisabeth Vytiska-Bistorfer; Alexandra Pawlik; Regina Promberger; Klaus Mayerhofer; Johannes Ott Journal: Reprod Biol Endocrinol Date: 2014-04-05 Impact factor: 5.211
Authors: Courtney C Carignan; Lidia Mínguez-Alarcón; Craig M Butt; Paige L Williams; John D Meeker; Heather M Stapleton; Thomas L Toth; Jennifer B Ford; Russ Hauser Journal: Environ Health Perspect Date: 2017-08-25 Impact factor: 9.031